Fig. 1 | British Journal of Cancer

Fig. 1

From: Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms

Fig. 1

Plausible explanations for immune checkpoint inhibitor resistance in MSI-H colorectal cancers (CRCs). Mutations in β2M and MHC-I result in dysfunction in the antigen presentation process and alterations in JAK2 and STAT lead to impaired interferon signalling. Upregulation of the WNT and TGF-β signalling causes increase in Foxp3+ TREG cells and negative regulatory signals on effector immune cells

Back to article page